Risks and limits of Helicobacter Genetik

The risks and limits of Helicobacter genetic testing lie primarily in its lack of clinical validation. While some direct-to-consumer (DTC) tests link single nucleotide polymorphisms (e.g., in IL1B, TNF‑α, or MUC1) to increased susceptibility to H. pylori infection or its complications (gastric cancer, peptic ulcer), the predictive value of these markers is low. H. pylori is reliably diagnosed via urea breath test, stool antigen test, or endoscopy with biopsy – not by genetics. A genetic risk score cannot confirm an active infection nor predict disease progression. Moreover, there is a real risk of misinterpretation: carrying a 'risk allele' does not mean one has or will develop an infection or disease. The evidence for clinical utility is weak; most associations come from population-based GWAS with small effect sizes. Without medical guidance, such tests may cause unnecessary anxiety or false reassurance. In summary, Helicobacter genetics is scientifically intriguing but currently lacks practical relevance. For reliable diagnosis and treatment decisions, conventional methods and professional medical advice remain essential.